TICKERNERD
Menu
OSCROSCRHealthcare · Healthcare Plans

OSCR Stock Forecast: Oscar Health, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$32
+0.03% on the day

The 11 Wall Street analysts covering Oscar Health, Inc. hold a median 12-month price target of $29 — -11.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 5 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$10.0B
Ticker Nerd rank
84 / 100
Median analyst target
$29
Analysts covering
11
Revenue$4.9B+70.4% y/y
Net income$361.8M
Free cash flow$2.1B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.8%
1M
+6.2%
YTD
+124.4%
1Y
+75.5%
From 52W high
−1.6%
From 52W low
+197.2%
$11
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OSCR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oscar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Momentum
93
Value
92
Revisions
72
Accruals
72
Quality
70
Volatility
25
Issuance
23
Size
16

Growth (96): Sales and profits are climbing, and climbing faster than before.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OSCR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OSCR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35$40$45Oct 25Jan 26Apr 26Jul 26OSCRHigh $39Median $29Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
3 Buy7 Hold1 Sell
Low $25Median $29High $39

The green dot is the last close — the median target sits −11.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026Wells FargoMaintainsEqual-Weight$20 → $27
7 Aug 2026BarclaysMaintainsOverweight$35 → $39
7 Aug 2026UBSMaintainsNeutral$20 → $26
10 June 2026BarclaysUpgradeOverweight$30 → $35
10 June 2026BarclaysUpgradeOverweight—
26 May 2026BarclaysMaintainsEqual-Weight—
7 May 2026BairdMaintainsNeutral—
7 May 2026BarclaysMaintainsEqual-Weight—
7 May 2026UBSMaintainsNeutral—
6 May 2026Wolfe ResearchInitiatesPeer Perform—
20 Apr 2026JefferiesUpgradeHold—
9 Jan 2026UBSUpgradeNeutral—
5 Jan 2026BarclaysUpgradeEqual-Weight—
11 Dec 2025Stephens & Co.InitiatesEqual-Weight—
26 Nov 2025Piper SandlerUpgradeOverweight—
13 Nov 2025Wells FargoMaintainsUnderweight—
10 Nov 2025BarclaysMaintainsUnderweight—
7 Nov 2025UBSMaintainsSell—
14 Oct 2025Goldman SachsInitiatesNeutral—
7 Oct 2025Wells FargoMaintainsUnderweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSCR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OSCR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Oscar Health, Inc. returned +75.5% against +20.0% for the S&P 500, dividends included.

OSCR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Oct 25Jan 26Apr 26Jul 26OSCRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OSCR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+80.9%
Analysts raising
8
Analysts cutting
0
Fundamentals

Oscar Health, Inc. (OSCR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
24.8×

Cheaper than 31% of US stocks

Price / sales
0.6×

Cheaper than 78% of US stocks

Price / book
4.8×

Cheaper than 22% of US stocks

EV / EBITDA
2.8×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
70.4%

Higher than 90% of US stocks

Earnings growth (YoY)
70.4%

Higher than 80% of US stocks

Gross margin
—
Operating margin
8.0%

Higher than 61% of US stocks

Net margin
3.6%

Higher than 56% of US stocks

Returns & dividend
Return on equity
34.3%

Higher than 89% of US stocks

Return on assets
4.5%

Higher than 73% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Oscar Health, Inc. (OSCR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oscar Health, Inc. has a market value of $10.0B and an enterprise value of $1.9B.

  • Revenue in the twelve months to 30 June 2026: $15.3B. The latest quarter grew 70.4% year on year.

  • Net income over the same four quarters: $550.9M, a 3.6% net margin.

  • Diluted earnings per share, trailing twelve months: $1.40.

  • Free cash flow in the twelve months to 30 June 2026: $4.4B.

  • Shares outstanding: 308.6M.

  • Trailing P/E: 24.8×; forward P/E: 17.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Oscar Health, Inc. employs 2,305 people — $6.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

OSCR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
OSCROscar Health, Inc.$10.0B
84
MOHMolina Healthcare, Inc.$10.3B
34
CNCCentene Corp.$33.0B
94
ALHCAlignment Healthcare, Inc.$2.8B
62
CLOVClover Health Investments Corp.$2.2B
67
PGNYProgyny, Inc.$2.0B
97
HUMHumana, Inc.$48.3B
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oscar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OSCR news & analysis

Oscar Health, Inc. (OSCR) Just Overtook the 20-Day Moving Average

Zacks Investment Research · 4 Sept 2026positive

Oscar Health, Inc. (OSCR) has reached an important support level and surpassed resistance at its 20-day moving average, suggesting a short-term bullish trend from a technical perspective, according to Zacks Investment Research.

Why it matters — OSCR watchers would care because crossing the 20-day moving average is a technical signal that could indicate a short-term upward trend in the stock.

Oscar Health, Inc. (OSCR) Just Overtook the 50-Day Moving Average

Zacks Investment Research · 4 Sept 2026positive

Oscar Health, Inc. (OSCR) recently broke above its 50-day moving average, a key technical level of support. According to Zacks Investment Research, this move suggests a short-term bullish trend for the stock from a technical perspective.

Why it matters — For investors watching OSCR, crossing above the 50-day moving average can signal improving short-term technical momentum and changing market sentiment around the stock.

Best Growth Stocks to Buy for September 4th

Zacks Investment Research · 4 Sept 2026positive

Zacks Investment Research added Oscar Health, Inc. (OSCR), along with BMA and ATI, to its Zacks Rank #1 (Strong Buy) growth stocks list on September 4, 2026. The designation places OSCR among stocks with top growth rankings according to Zacks' methodology.

Why it matters — The Zacks Strong Buy growth-stock designation signals that Oscar Health has been recognized with a top rating by a major independent research service.

Oscar Health Membership Surges but Profitability Remains Key

Zacks Investment Research · 2 Sept 2026neutral

Oscar Health reported a 46% jump in membership to 2.96 million. However, seasonal enrollment patterns and medical utilization keep profitability concerns in focus for the company.

Why it matters — OSCR watchers would care because strong membership growth is tempered by ongoing questions about whether profitability can be maintained given seasonal enrollment and medical utilization trends.

Best Momentum Stocks to Buy for September 2nd

Zacks Investment Research · 2 Sept 2026positive

Oscar Health, Inc. (OSCR) was included on the Zacks Investment Research Rank #1 (Strong Buy) momentum stocks list for September 2, 2026, alongside LQDT and GEO.

Why it matters — An OSCR watcher would care because being added to a Zacks #1 (Strong Buy) momentum stock list signals favorable analyst ranking and momentum recognition for the stock.

FAQ

Frequently asked questions about OSCR stock

What is the OSCR stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Oscar Health, Inc. have a median 12-month price target of $29, with estimates ranging from $25 to $39. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OSCR stock a buy right now?

Of the 11 analysts covering Oscar Health, Inc., 3 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Oscar Health, Inc. 84 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OSCR?

As at 5 Sept 2026, Oscar Health, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will OSCR stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies -11.6% from the last close, and Ticker Nerd's factor model ranks Oscar Health, Inc. 84 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OSCR stock forecast for 2030?

No analyst covering Oscar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $39 over the next 12 months.

How has OSCR stock performed over the past year?

Oscar Health, Inc. returned +75.5% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oscar Health, Inc. do?

Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States.

What is the latest news on OSCR?

The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Oscar Health, Inc. (OSCR) Just Overtook the 20-Day Moving Average". Oscar Health, Inc. (OSCR) has reached an important support level and surpassed resistance at its 20-day moving average, suggesting a short-term bullish trend from a technical perspective, according to Zacks Investment Research.

Company

About Oscar Health, Inc.

Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States. Oscar Health combines insurance coverage with a technology platform designed to help members access care, manage plans, and navigate the healthcare system. Its current offerings include individual and family health plans, small group coverage, and Medicare Advantage plans, along with technology solutions for providers and payors. The company operates in the managed health care and health services space, where it serves consumers and business customers through a data-driven, consumer-oriented model. Headquartered in New York, Oscar Health is positioned as a modern health insurer that integrates software, service, and clinical support across its insurance operations.

CEO Mr. Mark Thomas Bertolini · 2,305 employees · United States · https://www.hioscar.com